The mammalian target of rapamycin (mTOR) is a central regulator of cell growth and proliferation.
mTOR signaling is frequently dysregulated in oncogenic cells, and thus an attractive …

Many tumour antigens that do not arise from cancer cell-specific mutations are targets of
humoral and cellular immunity despite their expression on non-malignant cells. Thus, in …

… Moreover, looking at the C-terminal end of cryptic MAPs, we observed that the amino acid
usage differed from that of conventional MAPs. Indeed, up to four amino acids before the …

Tumor-specific antigens (TSAs) represent ideal targets for cancer immunotherapy, but few
have been identified thus far. We therefore developed a proteogenomic approach to enable …

… REFERENCE: Desmarais D, Zhong Y, Chakraborty R, Perreault highly polymorphic STR
loci that will allow an increase in the C, Busque L. Development of a highly polymorphic STR …

… To test this hypothesis, we analysed amino-acid usage at the four C-terminal amino acids
of individual MAPs and the four amino acids downstream of the C terminus (in the source …

MHC class I–associated peptides (MAPs) define the immune self for CD8 + T lymphocytes
and are key targets of cancer immunosurveillance. Here, the goals of our work were to …

Combining RNA sequencing, ribosome profiling, and mass spectrometry, we elucidate the
contribution of non-canonical translation to the proteome and major histocompatibility …

… Our group also described an association between pretransplantation titers of IgG autoantibodies
against the C-terminal perlecan fragment LG3 and the risk of acute vascular rejection in …

… 95C, followed by 40 cycles of 15 s at 95C and 1 min at 60C. All reactions were run in triplicate,
and the mean values were used for quantification. The mouse GAPDH or 18S ribosomal …